Last updated: 11/17/2026 12:40:24

Shingrix for Intramuscular Injection Drug Use Investigation

GSK study ID
212853
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Shingrix for Intramuscular Injection Drug Use Investigation
Trial description: The purpose of this prospective, descriptive, multi-center, drug utilization study was to assess the safety of Shingrix vaccine when administered in Japanese adults ≥50 Years of Age (YOA) for the first time.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Occurrence of adverse drug reactions (ADRs) (solicited adverse events), overall, by seriousness and by severity

Timeframe: During the 7-day follow-up period after vaccination (day of vaccination designated as Day 1) for each participant (observation period), collected between August 2020 to March 2025 (investigation period)

Occurrence of ADRs (unsolicited adverse events), overall, by seriousness and by severity

Timeframe: During the 30-day follow-up period after vaccination (day of vaccination designated as Day 1) for each participant (observation period), collected between August 2020 to March 2025 (investigation period)

Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
7830
Primary completion date:
2025-18-11
Observational study model:
Other
Time perspective:
Prospective
Clinical publications:
Not applicable
Medical condition
Herpes Zoster
Product
GSK1437173A
Collaborators
Not applicable
Study date(s)
October 2020 to November 2025
Type
Observational
Phase
Not applicable

Participation criteria

Sex
Female & Male
Age
50+ years
Accepts healthy volunteers
No
  • Participants vaccinated with Shingrix for the first time.
  • Obtaining informed consent from vaccinated person (and/or person’s representative).
  • None

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Tokyo, Japan, 107-0052
Status
Recruiting

Study documents

Study report synopsis
Available language(s): English
Clinical study report
Available language(s): English
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Finalized
Actual primary completion date
2025-18-11
Actual study completion date
2025-18-11

Plain language summaries

Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website